Type-1 interferons for the treatment of multiple sclerosis

• 1. 用拉喹莫德与干扰素-β的组合治疗多发性硬化症 [P] . 中国专利： CN103781355A . 2014-05-07
• 2. 使用特立氟胺与干扰素β的组合治疗多发性硬化症 [P] . 中国专利： CN102470116A . 2012-05-23
• 3. TYPE-1 INTERFERONS FOR TREATMENT OF MULTIPLE SCLEROSIS [P] . 世界知识产权组织专利： WO2012035113A1 . 2012-03-22

  机译： 治疗多发性硬化症的1型干扰素

• 4. Use of a combination of pentoxifylline with type - i - interferons for the treatment of multiple sclerosis [P] . NO982463L . 1998-05-29

  机译： 己酮可可碱与i型干扰素的联合应用治疗多发性硬化症。

• 5. Use of a combination of pentoxifylline with type - i - interferons for the treatment of multiple sclerosis [P] . NO982463D0 . 1998-05-29

  机译： 己酮可可碱与i型干扰素的联合应用治疗多发性硬化症。

• 1. Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab [J] . Stefan Gingele, Thomas Skripuletz, Roland Jacobs 中国神经再生研究（英文版） . 2020,第004期
• 2. Environmental enrichment as a promising strategy for aiding multiple sclerosis treatment [J] . Berenice Anabel Silva, Carina Cintia Ferrari 中国神经再生研究（英文版） . 2020,第009期
• 3. Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. [J] . Boz C, Oger J, Gibbs E, Multiple sclerosis: clinical and laboratory research . 2007,第9期
• 4. Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis [J] . Uros Rot, Alenka Horvat Ledinek Clinical neurology and neurosurgery . 2013,第Suppla1期
• 5. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: An evaluation from the food and drug administration adverse event reporting system and review of the literature [Colitis isquémica con interferonas tipo I usadas en el tratamiento de hepatitis c y esclerosis múltiple: Una evaluación del sistema de reporte de eventos adversos de la administración de drogas y alimentos y revisión de laliteratura] [J] . SalkA., StobaughD.J., DeepakP., The annals of pharmacotherapy . 2013,第4期
• 6. Pegylated Interferons In the Adjuvant Treatment of Melanoma [C] . Dirk Schadendorf International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009
• 7. Immunobiological studies of interferons in multiple sclerosis. [D] . Nguyen, Linh Thuy. 2001
• 8. Interferons in the Treatment of Multiple Sclerosis [O] . Mary Filipi, Samantha Jack 2020
• 9. Interferons in the Treatment of Multiple Sclerosis [O] . Mary Filipi, Samantha Jack 2019

• 1. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a [J] . Eckart Schott ,Friedemann Paul ,Jens T Wuerfel . 世界胃肠病学杂志：英文版 . 2007,第26期
• 2. Interferon-γ mRNA attenuates its own translation by activating PKR： A molecular basis for the therapeutic effect of interferon-β in multiple sclerosis [J] . Raymond Kaempfer . 细胞研究：英文版 . 2006,第2期
• 3. Intrathecal IgG synthesis in relapsing-remitting multiple sclerosis (MS) is decreased by natural human alpha interferon [J] . William A. Sheremata ,Alan Sazant ,Vincent Riesgo . 生命科学与技术进展（英文） . 2013,第7期
• 4. 多发性硬化症(MS)患者慢性脑脊髓静脉供血不足(CCSVI)的血管内介入治疗-美国介入放射学会(SIR)起草并由加拿大介入放射学会认可的申明 [C] . 周政 . 2010年全国介入放射学新技术研讨会 . 2010
• 5. 应用Markov模型对干扰素β-1α与干扰素β-1b治疗复发缓解型多发性硬化进行成本效果分析 [A] . 李红艳 . 2016